Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT05556460

Safety and Effectiveness Study of DragonFly-T System for Severe Tricuspid Regurgitation

Led by Hangzhou Valgen Medtech Co., Ltd · Updated on 2024-07-19

236

Participants Needed

2

Research Sites

173 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The primary objective of this trial is to demonstrate the safety and effectiveness of the DragonFly-T system in improving clinical outcomes in symptomatic patients with severe tricuspid regurgitation (TR), who are at intermediate or greater estimated risk for mortality or morbidity with tricuspid valve surgery. This randomized controlled trial will compare the investigational device (DragonFly-T system) to Control (Medical Therapy).

CONDITIONS

Official Title

Safety and Effectiveness Study of DragonFly-T System for Severe Tricuspid Regurgitation

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Patient has been adequately treated and stable for at least 30 days
  • Symptoms of tricuspid regurgitation despite optimized drug treatment
  • Determined to be at intermediate or higher risk for tricuspid valve surgery
  • New York Heart Association (NYHA) Cardiac function Class II-IVa
  • Suitable for transcatheter tricuspid valve repair and femoral vein access
  • Provided written informed consent before study participation
Not Eligible

You will not qualify if you...

  • Tricuspid valve leaflet anatomy preventing clip implantation or proper positioning, including calcification, severe coaptation defect, severe leaflet defects or clefts, and Epstein anomaly
  • Other serious heart valve diseases requiring intervention within 12 months
  • Tricuspid stenosis with cross-tricuspid pressure gradient ≥ 5 mmHg
  • Previous tricuspid valve surgery or transcatheter therapy
  • Presence of intracardiac thrombus, tumor, mass, or implants/thrombus in femoral vein or inferior vena cava
  • Inability to evaluate tricuspid valve anatomy by TTE or TEE
  • Participation in other drug or device clinical trials within 1 month prior
  • Any condition deemed inappropriate for study enrollment by researchers

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

West China Hospital of Sichuan University

Chengdu, Sichuan, China

Actively Recruiting

2

The Second Affiliated Hospital Zhejiang University School of Medicine

Hangzhou, Zhejiang, China, 310000

Actively Recruiting

Loading map...

Research Team

B

Bo Liu

CONTACT

S

Shuangjie Li

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here